Opinion
Volume 11:7, 2022

Journal of Metabolic Syndrome

ISSN: 2167-0943 Open Access

Obesity's Hematologic Consequences

Petra Langerbeins*

Department of Internal Medicine, CECAD Cluster of Excellence, University of Cologne, Kerpener Str 62, Germany

Introduction

The prevalence of obesity is rising and gradually influencing interactions between patients and doctors. We are aware of no single review that summarizes the effects of obesity on hematologic parameters and thrombotic risk, despite the substantial amount of data demonstrating that obesity is a state of low-grade inflammation. We played out a writing search which to a great extent surfaced observational examinations, with a couple of orderly surveys and meta-investigations of these investigations. Clinicians may feel more confident about obese patients' hematologic abnormalities if the aforementioned associations are recognized. We hope that this review will inspire subsequent research into the underlying mechanisms that cause these abnormalities, as well as the identification of modifiable risk factors and potential therapeutic targets to prevent the onset of likely obesity-associated conditions with significant morbidity and mortality, such as ID and VTE [1].

Description

Cytokines are a gathering of glycoproteins emitted by cells that manage various elements of the resistant system\. In intense cases, an overstated provocative reaction, named "hypercytokinemia", has been depicted, which will decide the guess of Coronavirus disease. The activation/anergy/apoptosis, proliferation, differentiation and maturation of lymphocytes and accessory cells are all cellular processes that are influenced by cytokines. Leukocyte distribution in tissues and circulating levels are also regulated by these molecules. In addition, cytokines have a modulatory effect on cells in a variety of body systems and organs. Utilitarian pleiotropy and overt repetitiveness are normal for cytokines, making their practical guideline a significant preventive and helpful objective in provocative sicknesses. In this context, the inflammatory response brought on by the COVID-19 infection primarily targets muscle tissue [2].

After 12 weeks of HFD, splenic CD4+ Teffs and Tregs from WT and TKO mice were subjected to genome-wide RNA sequencing (RNA-seq) to investigate the signaling pathways and biological processes impacted by KLF10 deficiency in CD4+ T cells. The same pathways, including cell growth and proliferation, cell death and survival and free radical scavenging, were identified by similar IPA of 569 genes that were differentially regulated in Teffs from HFD-fed WT and TKO mice. Oxidative phosphorylation, glycolysis and the PI3K-Akt-mTOR signaling pathways were among the top signaling pathways that were altered in HFD TKO Tregs and Teffs by either gene set enrichment analysis (GSEA) or IPA. These pathways were enriched from the dysregulated Treg and Teff gene sets [3].

Neutrophils are the primary source of S100A8/A9 and neutrophil depletion normalizes S100A8/A9 levels in the circulation of STZ-induced diabetic mice. Also, in our TIH model, we found that these neutrophils had higher levels of S100A9 than other cells that are known to express S100A8/A9, like monocytes and that these levels in neutrophils decreased when they were exposed to TIH. As a result, we hypothesized that TIH directly alters neutrophil metabolism and encourages the release of S100A8/A9. We used the Seahorse Extracellular Flux Analyzer to investigate real-time glycolytic rate. We found that when isolated human neutrophils were exposed to the glucose levels in our TIH model, their glycolytic rate significantly increased. This increase could be stopped by pre-incubating the cells with 2-deoxyglucose, a pan hexokinase inhibitor [4,5].

Conclusion

At the age of four weeks, KrasLA2 mice were placed on high-fat (60 percent kcal fat, Research Diets 12492) or low-fat (10 percent kcal fat, Research Diets 12240J) diets for the purpose of diet studies. As previously mentioned, mice received one gram of normal chow per mouse per day for caloric restriction. When treated water was replaced, water consumption was measured weekly. KCO mice drank 7.69 +/– 0.58 (s.d.), Untreated (control), aspirin, metformin, proglumide and dapagliflozin and 8.95 +/- 2. 24, 8.09 +/- 3. 21, 9.70 +/- 1.49 and 8.97 +/- 3.98 mL of drinking water daily, respectively. For each treatment condition, water intake was not statistically different from control (two-tailed student's t-test).

References

1. Phan, T.C. A., Jiake Xu and M. H. Zheng. "Interaction between osteoblast and osteoclast: Impact in bone disease." *Histol Histopathol* 19 (2004).
2. Delanaye, Pierre, Bernard E. Dubois, François Jouret and Jean-Marie Krzesinski, et al. "Parathormone and bone-specific alkaline phosphatase for the follow-up of bone turnover in hemodialysis patients: Is it so simple?." *Clin Chim Acta* 417 (2013): 35-38.
3. Ward, Richard A., Bärbel Schmidt, Jeannine Hullin and Günther F. Hillebrand, et al. "A comparison of on-line hemodiafiltration and high-flux hemodialysis: A prospective clinical study." *J Am Soc Nephrol* 11 (2000): 2344-2350.
4. Dekker, Marijke, Andreas Pasch, Frank van der Sande and Constantijn Konings, et al. "High-flux hemodialysis and high-volume hemodiafiltration improve serum calcification propensity." *PLoS One* 11 (2016): e0151508.
5. Judge, Timothy A., Christine L. Jackson, John C. Shaw and Brent A. Scott, et al. "Self-efficacy and work-related performance: The integral role of individual differences." *J Appl Soc Psychol* 92 (2007): 107.

***Address for Correspondence:** Petra Langerbeins, Department of Internal Medicine, CECAD Cluster of Excellence, University of Cologne, Kerpener Str 62, Germany; E-mail: petral@uk-koeln.de*

Date of Submission: 29 June, 2022, Manuscript No. jms-22-81052; **Editor Assigned:** 01 July, 2022, PreQC No. P-81052; **Reviewed:** 14 July, 2022, QC No. Q-81052; **Revised:** 18 July, 2022, Manuscript No. R-81052; **Published:** 25 July, 2022, DOI: 10. 37421/ 2167-0943.2022.11.285

How to cite this article: Langerbeins, Petra. "Obesity's Hematologic Consequences." J Metabolic Synd 11 (2022): 285.